Please assess the completion status of the following clinical trial:

Trial Title: Creatine as a Treatment Option for Depression in Methamphetamine Using Females

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Female gender, ages 18-64 years inclusive~2. Diagnosis of MA dependence or abuse within the past 12 months, with MA preferred drug of abuse, identified by the SCID-I-RV~3. Current diagnosis of Major Depressive Disorder identified by the SCID-I-RV~4. Current HAM-D17 score of \> 15~Exclusion Criteria:~1. Diagnosis of bipolar disorder, schizophrenia, or schizoaffective disorder, identified by the SCID-I-RV~2. History of or current diagnosis of renal disease, such as chronic renal failure, acute renal failure or end stage renal disease~3. Diabetes type I or II~4. Colitis or diverticulitis~5. Seizure disorder~6. Current serious suicide risk identified by the Columbia Severity Suicide Rating Severity~7. Current treatment with an antipsychotic, mood stabilizer, or antidepressant~8. Positive HIV test~9. Active Hepatitis C~10. Contraindication to magnetic resonance scan

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Creatine monohydrate (Type: EXPERIMENTAL): 14 female depressed methamphetamine users received 5 grams of creatine monohydrate daily for eight weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).